摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,6-dichloro-4-hydrazinylpyridine | 893616-23-4

中文名称
——
中文别名
——
英文名称
2,6-dichloro-4-hydrazinylpyridine
英文别名
(2,6-dichloropyridin-4-yl)hydrazine
2,6-dichloro-4-hydrazinylpyridine化学式
CAS
893616-23-4
化学式
C5H5Cl2N3
mdl
MFCD06654056
分子量
178.021
InChiKey
ZOZAXELOAJLSFK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    50.9
  • 氢给体数:
    2
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    反式-4-甲氧基-3-丁烯-2-酮2,6-dichloro-4-hydrazinylpyridine对甲苯磺酸 作用下, 以 乙醇 为溶剂, 反应 18.0h, 以38%的产率得到2,6-dichloro-4-(5-methyl-1H-pyrazol-1-yl)pyridine
    参考文献:
    名称:
    [EN] ALKYNYL ALCOHOLS AND METHODS OF USE
    [FR] ALCOOLS ALCYNYLIQUES ET LEURS PROCÉDÉS D'UTILISATION
    摘要:
    该发明涉及以下式的化合物(0):其中A1-A8,R4和R5分别具有如本文所述的含义。该式(0)的化合物及其药物组合物在治疗观察到NF-kB信号不良或过度激活的疾病和紊乱中是有用的。
    公开号:
    WO2015025026A1
  • 作为产物:
    描述:
    2,4,6-三氯吡啶一水合肼 作用下, 以 四氢呋喃 为溶剂, 以34%的产率得到2,6-dichloro-4-hydrazinylpyridine
    参考文献:
    名称:
    [EN] ALKYNYL ALCOHOLS AND METHODS OF USE
    [FR] ALCOOLS ALCYNYLIQUES ET LEURS PROCÉDÉS D'UTILISATION
    摘要:
    该发明涉及以下式的化合物(0):其中A1-A8,R4和R5分别具有如本文所述的含义。该式(0)的化合物及其药物组合物在治疗观察到NF-kB信号不良或过度激活的疾病和紊乱中是有用的。
    公开号:
    WO2015025026A1
点击查看最新优质反应信息

文献信息

  • [EN] ALKYNYL ALCOHOLS AND METHODS OF USE<br/>[FR] ALCOOLS ALCYNYLIQUES ET LEURS PROCÉDÉS D'UTILISATION
    申请人:HOFFMANN LA ROCHE
    公开号:WO2015025026A1
    公开(公告)日:2015-02-26
    The invention relates to compounds of Formula (0): wherein A1-A8, R4 and R5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
    该发明涉及以下式的化合物(0):其中A1-A8,R4和R5分别具有如本文所述的含义。该式(0)的化合物及其药物组合物在治疗观察到NF-kB信号不良或过度激活的疾病和紊乱中是有用的。
  • CRTH2 Receptor Ligands For Medicinal Uses
    申请人:Ulven Trond
    公开号:US20090099189A1
    公开(公告)日:2009-04-16
    Compounds of formula (I) are useful for the treatment of disease responsive to modulation of CRTH2 receptor activity, such as asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis, wherein A represents a carboxyl group —COON, or a carboxyl bioisostere; A 1 , is hydrogen or methyl; ring Ar 1 is an optionally substituted phenyl ring 5- or 6-membered monocyclic heteroaryl ring, in which AA 1 CHO— and L2 are linked to adjacent ring atoms; rings Are 2 , Ar 3 each independently represent a phenyl or 5- or 6-membered monocyclic heteroaryl ring, or a bicyclic ring system consisting of a 5- or 6-membered carbocyclic or heterocyclic ring which is benz-fused or fused to a 5- or 6-membered monocyclic heteroaryl ring, said ring or ring system being optionally substituted; t is 0 or 1; L2 and L3 are linker radicals as defined in the description.
    式(I)的化合物可用于治疗对CRTH2受体活性调节敏感的疾病,例如哮喘、鼻炎、过敏性气道综合症和过敏性鼻支气管炎,其中A代表羧基—COON或羧基生物同位素;A1为氢或甲基;环Ar1是一个可选取代的苯环5-或6-成员的单环杂环,其中AA1CHO—和L2与相邻的环原子连接;环Are2,Ar3各自独立地表示一个苯环或5-或6-成员的单环杂环,或由一个5-或6-成员的碳环或杂环组成的双环系统,该环或环系统被苯并或与一个5-或6-成员的单环杂环融合,该环或环系统是可选取代的;t为0或1;L2和L3是如描述中所定义的连接基团。
  • Structure–Activity Relationships and Optimization of 3,5-Dichloropyridine Derivatives As Novel P2X<sub>7</sub>Receptor Antagonists
    作者:Won-Gil Lee、So-Deok Lee、Joong-Heui Cho、Younghwan Jung、Jeong-hyun Kim、Tran T. Hien、Keon-Wook Kang、Hyojin Ko、Yong-Chul Kim
    DOI:10.1021/jm2012326
    日期:2012.4.26
    Screening of a library of chemical compounds showed that the dichloropyridine-based analogue 9 was a novel P2X(7) receptor antagonist. To optimize its activity, we assessed the structure-activity relationships (SAR) of 9, focusing on the hydrazide linker, the dichloropyridine skeleton, and the hydrophobic acyl (R-2) group. We found that the hydrazide linker and the 3,5-disubstituted chlorides in the pyridine skeleton were critical for P2X(7) antagonistic activity and that the presence of hydrophobic polycycloalkyl groups at the R-2 position optimized antagonistic activity. In the EtBr uptake assay in hP2X(7)-expressing HEK293 cells, the optimized antagonists, 5i and 52, had IC50 values of 4.9 and 13 nM, respectively. The antagonistic effects of 51 and 52 were paralleled by their ability to inhibit the release of the pro-inflammatory cytokine, IL-1 beta, by LPS/IFN-gamma/BzATP stimulation of THP-1 cells (IC50 = 1.3 and 9.2 nM, respectively). In addition, 52 strongly inhibited iNOS/COX-2 expression and NO production in THP-1 cells, further indicating that this compound blocks inflammatory signaling and suggesting that the dichloropyridine analogues may be useful in developing P2X(7) receptor targeted anti-inflammatory agents.
  • US8022063B2
    申请人:——
    公开号:US8022063B2
    公开(公告)日:2011-09-20
  • ALKYNYL ALCOHOLS AND METHODS OF USE
    申请人:Genentech, Inc.
    公开号:US20150057260A1
    公开(公告)日:2015-02-26
    The invention relates to compounds of Formula (0): wherein A 1 -A 8 , R 4 and R 5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
    该发明涉及具有以下结构的化合物(0):其中A1-A8,R4和R5分别具有如本文所述的含义。 公式(0)的化合物及其药物组成物在治疗观察到NF-kB信号不受欢迎或过度激活的疾病和紊乱中是有用的。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-